Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Informe acción SEHK:1349

Capitalización de mercado: HK$6.6b

Salud financiera de hoja de balance de Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

Salud financiera controles de criterios 6/6

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd tiene un patrimonio de accionistas total de CN¥2.4B y una deuda total de CN¥0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CN¥2.9B y CN¥518.1M respectivamente. El BAIT de Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd es de CN¥77.2M, por lo que su ratio de cobertura de intereses es de -15.7. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥1.2B.

Información clave

0.2%

Ratio deuda-patrimonio

CN¥4.91m

Deuda

Ratio de cobertura de intereses-13.2x
EfectivoCN¥1.23b
PatrimonioCN¥2.36b
Total pasivoCN¥464.49m
Activos totalesCN¥2.83b

Actualizaciones recientes sobre salud financiera

Recent updates

What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

Apr 12
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Mar 22
We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Mar 07
Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Feb 20
Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Feb 07
Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Jan 25
Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Jan 12
Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Dec 28
Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Dec 15
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Dec 03
Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 21
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥1.9B) de 1349 superan a sus pasivos a corto plazo (CN¥505.0M).

Pasivo a largo plazo: Los activos a corto plazo de 1349 (CN¥1.9B) superan a sus pasivos a largo plazo (CN¥13.1M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: 1349 tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de 1349 ha pasado de 15.7% a 0.2% en los últimos 5 años.

Cobertura de la deuda: La deuda de 1349 está bien cubierta por el flujo de caja operativo (5610.4%).

Cobertura de intereses: 1349 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.


Hoja de balance


Descubre empresas con salud financiera